Covered recipient · General Payments record
RAMYA EMBAR SRINIVASAN
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2018–2022
$1,623.31
- Reported across 96 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2022 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $322.95 | 18 |
By paying entity
PY2022 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $145.91 | 8 |
| Abbott Laboratories | $42.13 | 2 |
| Xeris Pharmaceuticals, Inc. | $39.33 | 2 |
| ABBVIE INC. | $28.09 | 2 |
| IBSA Pharma Inc. | $21.68 | 1 |
| Insulet Corporation | $21.14 | 1 |
| Lilly USA, LLC | $12.49 | 1 |
| DEXCOM, INC. | $12.18 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2022 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $20.80 | 02/08/2022 | Food and Beverage | Undisputed | 01/23/2026 | 920554239 | CMS |
| Abbott Laboratories | $21.33 | 05/13/2022 | Food and Beverage | Undisputed | 01/23/2026 | 910344665 | CMS |
| ABBVIE INC. | $13.35 | 04/01/2022 | Food and Beverage | Undisputed | 01/23/2026 | 890920853 | CMS |
| ABBVIE INC. | $14.74 | 10/27/2022 | Food and Beverage | Undisputed | 01/23/2026 | 890920855 | CMS |
| Dexcom, Inc. | $12.18 | 02/01/2022 | Food and Beverage | Undisputed | 01/23/2026 | 957342871 | CMS |
| IBSA Pharma Inc. | $21.68 | 03/02/2022 | Food and Beverage | Undisputed | 01/23/2026 | 890023469 | CMS |
| Insulet Corporation | $21.14 | 01/31/2022 | Food and Beverage | Undisputed | 01/23/2026 | 933135097 | CMS |
| Lilly USA, LLC | $12.49 | 04/08/2022 | Food and Beverage | Undisputed | 01/23/2026 | 918200547 | CMS |
| Novo Nordisk Inc | $14.20 | 01/04/2022 | Food and Beverage | Undisputed | 01/23/2026 | 899076610 | CMS |
| Novo Nordisk Inc | $16.82 | 02/16/2022 | Food and Beverage | Undisputed | 01/23/2026 | 898653689 | CMS |
| Novo Nordisk Inc | $17.41 | 04/05/2022 | Food and Beverage | Undisputed | 01/23/2026 | 899076773 | CMS |
| Novo Nordisk Inc | $18.21 | 08/19/2022 | Food and Beverage | Undisputed | 01/23/2026 | 898932475 | CMS |
| Novo Nordisk Inc | $16.26 | 08/22/2022 | Food and Beverage | Undisputed | 01/23/2026 | 899076618 | CMS |
| Novo Nordisk Inc | $18.10 | 10/01/2022 | Food and Beverage | Undisputed | 01/23/2026 | 898653695 | CMS |
| Novo Nordisk Inc | $22.27 | 10/19/2022 | Food and Beverage | Undisputed | 01/23/2026 | 899530949 | CMS |
| Novo Nordisk Inc | $22.64 | 12/02/2022 | Food and Beverage | Undisputed | 01/23/2026 | 899030091 | CMS |
| Xeris Pharmaceuticals, Inc. | $21.04 | 02/15/2022 | Food and Beverage | Undisputed | 01/23/2026 | 946489647 | CMS |
| Xeris Pharmaceuticals, Inc. | $18.29 | 03/25/2022 | Food and Beverage | Undisputed | 01/23/2026 | 946489649 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022
- Generated from
- OP_DTL_GNRL_PGYR2022_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.